A new RNA treatment to reduce heart scarring in Duchenne muscular dystrophy
Official title: Targeting myocardial fibrosis with a novel noncoding RNA in Duchenne muscular dystrophy
Funded at Cedars-Sinai Medical Center · NIH-11252176 · Data updated 2026-11-12
A new RNA-based medicine aims to reduce heart scarring in people with Duchenne muscular dystrophy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | January 12, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $635,801 |
| NIH project number | 5R01HL167921-03 |
| Project ID | NIH-11252176 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with Duchenne muscular dystrophy, especially those with early signs of heart involvement or at risk for cardiomyopathy, would be the most relevant candidates.
✕Less likely to help
People without Duchenne muscular dystrophy or those with very advanced, irreversible heart failure are unlikely to benefit from this approach.
What this research studies
Researchers are developing TY4, a small chemically modified RNA inspired by molecules found in heart-cell vesicles, to reduce fibrosis (scarring) in the heart of people with Duchenne muscular dystrophy. In mouse models of DMD, TY4 showed disease-modifying effects and worked when given by mouth together with the protein casein. The team is studying how TY4 changes the behavior of immune cells called macrophages and the genes they turn on or off. If the approach continues to look promising, the work could move toward testing in people.
Why it matters
Potential benefit: If successful, TY4 could reduce heart scarring in Duchenne muscular dystrophy and help preserve heart function.
How similar studies have gone: This is a novel class of RNA drug: related Y-RNA-derived molecules have shown benefit in animal models, but TY4 itself has so far only shown promise in mouse studies.
Where this research is happening
-
Cedars-Sinai Medical Center
Los Angeles, United States Active
Researchers
- Principal investigator: Rogers, Russell — Cedars-Sinai Medical Center
- Study coordinator: Rogers, Russell
Related research
Other NIH-funded projects on the same topics.
-
Investigating a new RNA treatment for heart issues in Duchenne muscular dystrophy
This study is looking at a new treatment using a special type of RNA called TY4, which comes from tiny particles in the body, to help reduce heart scarring in people with Duchenne muscular dystrophy (DMD), and it’s taken by mouth along with a protein from breast milk to make it easier for patients to use.
-
Advancing manufacturing and release testing for a Duchenne gene editing therapy
A project to optimize how a dual-vector AAV gene editing treatment for Duchenne muscular dystrophy is made and tested, so it can move toward clinical use.
-
Understanding why Duchenne Muscular Dystrophy worsens and how to stop it
A research team at USC is studying Duchenne muscular dystrophy to find out why the disease continues to progress and how to interrupt harmful changes in muscle tissue.
-
Stopping steroid-related muscle and bone wasting in Duchenne muscular dystrophy
Researchers are testing ways to protect muscles and bones in people with Duchenne muscular dystrophy who take long-term steroid medicines.
-
MR clues to how nNOS affects energy use and blood flow in Becker and Duchenne muscular dystrophy
This project looks at how advanced MRI tests can track muscle energy and blood flow changes in people with Becker and Duchenne muscular dystrophy as new gene therapies are explored.
-
Digital motor-skill tracking for infants with Duchenne Muscular Dystrophy using wearables
A wearable-sensor project aims to quietly track and quantify how motor skills develop in babies and young boys with Duchenne Muscular Dystrophy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.